With this prospective, randomized, controlled trial the investigators want to investigate effects of a prolonged repetitive Peripheral Magnetic Stimulation (rPMS) intervention on Achilles tendinopathy and compare it to a well established intervention. This may provide clinicians with a new, non-pharmacological, non-invasive, near painless approach to treat tendinopathy. Although promising results with comparable devices exist, a direct and valid conclusion on the overall clinical performance of the investigational device cannot be drawn. This is mainly due to different treatment protocols used in the literature and due to the lack of insight in the technical documentation of comparable devices. Further, the applied magnetic fields vary in their amplitude, frequency, waveform and/or stimulation durations. Therefore, the main goal of this clinical investigation is the collection of clinical data on the clinical performance of the investigational device. This clinical data will subsequently serve as a main source for the clinical evaluation of the medical device.
Tendons are collagenous tissues that link muscle to bone, and in best case, a painless transmission of force allows voluntary movement over a life time. Although tendons show long time underestimated repair and remodelling capacities, some of them (e.g. the human patellar or Achilles tendon) remain quite prone to injury. To make things worse, tendinous tissue reveals incomplete healing capacities and treatments seem to be ineffective to avoid the high injury recurrence rate and/or the occurrence of chronic tendon pain. Thus, both elite and recreational athletes, as well as the non-sporting population or workplace employees often suffer from symptoms like tendon swelling, localized tenderness, activity related pain and impaired performance, also known as tendinopathy. Such pain-induced restriction of mobility frequently means the end of a sporting carrier, deteriorates the quality of life and patients have to live with all harmful consequences of physical inactivity. One tendon most commonly afflicted by this debilitating musculoskeletal injury is the Achilles tendon. Although it is the strongest tendon in our body, the prevalence for tendinopathy can be as high as 56% among certain athletes. The repetitive peripheral magnetic stimulation (rPMS) works through a deep operating, focused and painless stimulation mechanism generated by pulsed magnetic fields. This intervention is already successfully in use to accelerate the healing of bone fractures and to enhance the healing of operated rotator cuff tears. Additionally, data on in vitro tendon cells indicate the positive effect of rPMS on tendon tissue by stimulating cell proliferation, up-regulating tendon-specific gene expression and releasing anti-inflammatory cytokines and growth factors. More interestingly, intervention studies on the healing of rotator cuff tendon-to-bone injuries in rat models show increases in tendon stiffness and modulus and enhanced collagen organization, and type I collagen expression after prolonged rPMS without showing adverse effects in any mechanical or histological property. These results strongly support the hypothesis that rPMS might be effective in treating Achilles tendinopathy in humans. This intervention might reduce pain and functional limitations, reverse tendon degenerative changes and increase the impaired tendon mechanical and material properties.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility. The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla. The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected. For comfortable transport and application the product is compact and portable.
Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day. The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling.
Gesundheitszentrum Woergl
Wörgl, Tyrol, Austria
RECRUITINGChange of the experience of pain and functionality with the Victorian Institute of Sports Assessment questionnaire (VISA-A)
Change of the experience of pain and functionality as assessed by the Victorian Institute of Sports Assessment questionnaire (VISA-A). The VISA-A questionnaire is a validated questionnaire with good test-retest, intra-rater and inter-rater reliability and is especially designed for patients with Achilles tendinopathy. The maximum score that can be achieved on the question is 100, and would be the score of person who is completely asymptomatic. A lower score indicates more symptoms and greater limitation of physical activity.
Time frame: "Week 0", "Week 12"
Change of the experience of pain at exertion as assessed by the Visual Analogue Scale (VAS)
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("no pain"), 100 means high (Pain as bad as could possibly be).
Time frame: "Week 4", "Week 12"
Percentage of participants with an anticipated adverse event of special interest
Percentage of participants with an anticipated adverse event of special interest (muscle twitching, local warming and initial pain excitement). The occurrence of the expected side-effects is not definitely clear based on literature and pre-clinical investigations.
Time frame: "Week 4"
Change of the experience of pain and functionality with the Victorian Institute of Sports Assessment questionnaire (VISA-A)
Change of the experience of pain and functionality as assessed by the Victorian Institute of Sports Assessment questionnaire (VISA-A). The VISA-A questionnaire is a validated questionnaire with good test-retest, intra-rater and inter-rater reliability and is especially designed for patients with Achilles tendinopathy. The maximum score that can be achieved on the question is 100, and would be the score of person who is completely asymptomatic. A lower score indicates more symptoms and greater limitation of physical activity.
Time frame: "Week 0", "Week 2"
Change of the experience of pain and functionality with the Victorian Institute of Sports Assessment questionnaire (VISA-A)
Change of the experience of pain and functionality as assessed by the Victorian Institute of Sports Assessment questionnaire (VISA-A). The VISA-A questionnaire is a validated questionnaire with good test-retest, intra-rater and inter-rater reliability and is especially designed for patients with Achilles tendinopathy. The maximum score that can be achieved on the question is 100, and would be the score of person who is completely asymptomatic. A lower score indicates more symptoms and greater limitation of physical activity.
Time frame: "Week 0", "Week 4"
Change of the experience of pain and functionality with the Victorian Institute of Sports Assessment questionnaire (VISA-A)
Change of the experience of pain and functionality as assessed by the Victorian Institute of Sports Assessment questionnaire (VISA-A). The VISA-A questionnaire is a validated questionnaire with good test-retest, intra-rater and inter-rater reliability and is especially designed for patients with Achilles tendinopathy. The maximum score that can be achieved on the question is 100, and would be the score of person who is completely asymptomatic. A lower score indicates more symptoms and greater limitation of physical activity.
Time frame: "Week 0", "Week 6"
Change of the experience of pain and functionality with the Victorian Institute of Sports Assessment questionnaire (VISA-A)
Change of the experience of pain and functionality as assessed by the Victorian Institute of Sports Assessment questionnaire (VISA-A). The VISA-A questionnaire is a validated questionnaire with good test-retest, intra-rater and inter-rater reliability and is especially designed for patients with Achilles tendinopathy. The maximum score that can be achieved on the question is 100, and would be the score of person who is completely asymptomatic. A lower score indicates more symptoms and greater limitation of physical activity.
Time frame: "Week 0", "Week 8"
Change of the experience of pain and functionality with the Victorian Institute of Sports Assessment questionnaire (VISA-A)
Change of the experience of pain and functionality as assessed by the Victorian Institute of Sports Assessment questionnaire (VISA-A). The VISA-A questionnaire is a validated questionnaire with good test-retest, intra-rater and inter-rater reliability and is especially designed for patients with Achilles tendinopathy. The maximum score that can be achieved on the question is 100, and would be the score of person who is completely asymptomatic. A lower score indicates more symptoms and greater limitation of physical activity.
Time frame: "Week 0", "Week 24"
Change of the experience of pain at exertion with Visual Analogue Scale (VAS)
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("no pain"), 100 means high (Pain as bad as could possibly be).
Time frame: "Week 0", "Week 2"
Change of the experience of pain at exertion with Visual Analogue Scale (VAS)
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("no pain"), 100 means high (Pain as bad as could possibly be).
Time frame: "Week 0", "Week 4"
Change of the experience of pain at exertion with Visual Analogue Scale (VAS)
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("no pain"), 100 means high (Pain as bad as could possibly be).
Time frame: "Week 0", "Week 6"
Change of the experience of pain at exertion with Visual Analogue Scale (VAS)
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("no pain"), 100 means high (Pain as bad as could possibly be).
Time frame: "Week 0", "Week 8"
Change of the experience of pain at exertion with Visual Analogue Scale (VAS)
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("no pain"), 100 means high (Pain as bad as could possibly be).
Time frame: "Week 0", "Week 24"
Patient Satisfaction: Psychometric response scale with Visual Analogue Scale (VAS).
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("not satisfied at all"), 100 means high (Satisfaction could not be higher).
Time frame: "Week 0"
Patient Satisfaction: Psychometric response scale with Visual Analogue Scale (VAS).
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("not satisfied at all"), 100 means high (Satisfaction could not be higher).
Time frame: "Week 2"
Patient Satisfaction: Psychometric response scale with Visual Analogue Scale (VAS).
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("not satisfied at all"), 100 means high (Satisfaction could not be higher).
Time frame: "Week 4"
Patient Satisfaction: Psychometric response scale with Visual Analogue Scale (VAS).
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("not satisfied at all"), 100 means high (Satisfaction could not be higher).
Time frame: "Week 6"
Patient Satisfaction: Psychometric response scale with Visual Analogue Scale (VAS).
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("not satisfied at all"), 100 means high (Satisfaction could not be higher).
Time frame: "Week 8"
Patient Satisfaction: Psychometric response scale with Visual Analogue Scale (VAS).
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("not satisfied at all"), 100 means high (Satisfaction could not be higher).
Time frame: "Week 12"
Patient Satisfaction: Psychometric response scale with Visual Analogue Scale (VAS).
Psychometric response scale with continuous aspect (Visual Analogue Scale (VAS)). 0 means low ("not satisfied at all"), 100 means high (Satisfaction could not be higher).
Time frame: "Week 24"
Change of Achilles transverse thickness
Maximum thickness will be recorded in the midportion of the affected Achilles tendon
Time frame: "Week 0", "Week 6"
Change of Achilles transverse thickness
Maximum thickness will be recorded in the midportion of the affected Achilles tendon
Time frame: "Week 0", "Week 12"
Change of Neovascularization in the Achilles tendon
Doppler activity measured with real time ultrasonography in a longitudinal and sagittal view.
Time frame: "Week 0", "Week 4"
Change of Neovascularization in the Achilles tendon
Doppler activity measured with real time ultrasonography in a longitudinal and sagittal view.
Time frame: "Week 0", "Week 12"
Usability, graded on a scale from 1 to 5 (1 means low usability, 5 means high usability)
The usability characteristics contribute to the summative evaluation of the usability of the device under investigation. 1 means low usability, 5 means high usability.
Time frame: "Week 2"
Usability, graded on a scale from 1 to 5 (1 means low usability, 5 means high usability)
The usability characteristics contribute to the summative evaluation of the usability of the device under investigation. 1 means low usability, 5 means high usability.
Time frame: "Week 8"
Usability, graded on a scale from 1 to 5 (1 means low usability, 5 means high usability)
The usability characteristics contribute to the summative evaluation of the usability of the device under investigation. 1 means low usability, 5 means high usability.
Time frame: "Week 12"
Percentage of participants with an anticipated adverse event of special interest.
The percentage of participants with an anticipated adverse event of special interest (muscle twitching, local warming and initial pain excitement). The occurrence of the expected side-effects is not definitely clear based on literature and pre-clinical investigations.
Time frame: "Week 0"
Percentage of participants with an anticipated adverse event of special interest.
The percentage of participants with an anticipated adverse event of special interest (muscle twitching, local warming and initial pain excitement). The occurrence of the expected side-effects is not definitely clear based on literature and pre-clinical investigations.
Time frame: "Week 2"
Percentage of participants with an anticipated adverse event of special interest.
The percentage of participants with an anticipated adverse event of special interest (muscle twitching, local warming and initial pain excitement). The occurrence of the expected side-effects is not definitely clear based on literature and pre-clinical investigations.
Time frame: "Week 6"
Percentage of participants with an anticipated adverse event of special interest.
The percentage of participants with an anticipated adverse event of special interest (muscle twitching, local warming and initial pain excitement). The occurrence of the expected side-effects is not definitely clear based on literature and pre-clinical investigations.
Time frame: "Week 8"
Percentage of participants with an anticipated adverse event of special interest.
The percentage of participants with an anticipated adverse event of special interest (muscle twitching, local warming and initial pain excitement). The occurrence of the expected side-effects is not definitely clear based on literature and pre-clinical investigations.
Time frame: "Week 12"
Percentage of participants with an anticipated adverse event of special interest.
The percentage of participants with an anticipated adverse event of special interest (muscle twitching, local warming and initial pain excitement). The occurrence of the expected side-effects is not definitely clear based on literature and pre-clinical investigations.
Time frame: "Week 24"
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.